Drug intelligence / Profile preview

nordimaprit

Development stage: Preclinical
Modality: Small Molecules

Overview

Nordimaprit is a histamine H2 receptor agonist that has demonstrated the ability to decrease tyrosinase activity in cultured human melanoma cells. This leads to a significant reduction and eventual loss of pigment. Its mechanism of action involves three components: the induction of an inhibitory activity against tyrosinase, an increased rate of tyrosinase degradation, and a long-term down-regulation of tyrosinase expression. The depigmenting effect was shown to be long-lasting, with cells remaining amelanotic for weeks after drug removal.

Targets

HRH2 (Histamine H2 Receptor)

Beyond the preview

Go deeper on nordimaprit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nordimaprit.

Explore the full profile